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Abstract
Background: There is a lack of agreement on which gastric cancer screening method is the most effective in the general
population. The present study compared the relative performance of upper-gastrointestinal series (UGIS) and endoscopy
screening for gastric cancer.
Methods: A population-based study was conducted using the National Cancer Screening Program (NCSP) database. We
analyzed data on 2,690,731 men and women in Korea who underwent either UGIS or endoscopy screening for gastric cancer
between January 1, 2002 and December 31, 2005. Final gastric cancer diagnosis was ascertained through linkage with the
Korean Central Cancer Registry. We calculated positivity rate, gastric cancer detection rate, interval cancer rate, sensitivity,
specificity, and positive predictive value of UGIS and endoscopy screening.
Results: The positivity rates for UGIS and endoscopy screening were 39.7 and 42.1 per 1,000 screenings, respectively. Gastric
cancer detection rates were 0.68 and 2.61 per 1,000 screenings, respectively. In total, 2,067 interval cancers occurred within
1 year of a negative UGIS screening result (rate, 1.17/1,000) and 1,083 after a negative endoscopy screening result (rate,
1.17/1,000). The sensitivity of UGIS and endoscopy screening to detect gastric cancer was 36.7 and 69.0%, respectively, and
specificity was 96.1 and 96.0%. The sensitivity of endoscopy screening to detect localized gastric cancer was 65.7%, which
was statistically significantly higher than that of UGIS screening.
Conclusion: Overall, endoscopy performed better than UGIS in the NCSP for gastric cancer. Further evaluation of the impact
of these screening methods should take into account the corresponding costs and reduction in mortality.
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Introduction
Gastric cancer is the fourth most common type of cancer
(988,602 new cases, 7.8% of all new cancer cases in 2008) and the
second most common cause of cancer death (737,419 deaths
annually) in the world [1]. Some Asian countries, including China,
Japan, and the Republic of Korea, have the highest gastric cancer
incidences in the world [2]. Although the incidence of gastric
cancer has declined in Korea in recent decades, it remains the
most common cancer affecting the population [3].
Because the prognosis of early gastric cancer is favorable, high-
prevalence countries have sought to reduce the disease burden by
providing screening to average-risk populations. However, as
gastric cancer screening is still fairly uncommon, and there is a
paucity of data from Asia to support the establishment of gastric
cancer screening programs [4,5,6,7,8,9,10]. Japan is one excep-
tion, and has been conducting mass gastric cancer screening using
photofluorography (via indirect upper-gastrointestinal series) since
1960. Photofluorography screening is usually performed in a
mobile van by the indirect x-ray method, in which a barium meal
is used to make an image of the stomach. The early detection and
consequent higher cure rates of gastric cancer and have led to a
remarkable improvement in survival rates in Japan [6,11,12].
Cohort and case-control studies have also generally revealed a
decreased risk of gastric cancer mortality in patients who have
undergone photofluorography screening [5,6,13]. Although pop-
ulation-based photofluorography screening for gastric cancer has
been mandated as a public policy matter in Japan, other
opportunistic screening methods are also used in clinical settings
throughout Asia, including endoscopy, serum pepsinogen testing,
and Helicobacter pylori antibody testing [14].
Endoscopy is generally accepted as the gold standard for the
diagnosis and clinicopathological evaluation of gastric cancer.
Endoscopic examination has been predominantly used to screen
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symptomatic individuals, and to distinguish patients with gastric
cancer from those with comparatively benign diseases, such as
peptic ulcers. Moreover, less invasive endoscopy procedures, such
as endoscopic mucosal resection and endoscopic submucosal
dissection, have recently been established as treatments for early
gastric cancer, without the risk of lymph node metastasis [15]. In
recent years, endoscopy has been widely conducted as part of
routine health check-ups. Some authors have reported higher
detection rates of early gastric cancer with endoscopy than with
UGIS. In a study conducted in Niigata, Japan, the detection of
gastric cancer by endoscopy screening was about 2.7 times higher
than that by direct or indirect radiography screening [16]. Despite
promising results, the evidence regarding the effectiveness and
complications of endoscopy screening, as well as the acceptance of
individuals at average risk for gastric cancer to undergo the
procedure, remains insufficient to justify its use in routine
screening [17]. In Korea, a nationwide gastric cancer screening
program was started in 1999 as part of the National Cancer
Screening Program (NCSP) [18]. The NCSP recommends
biennial gastric cancer screening for men and women aged 40
years or older, by either upper-gastrointestinal series (UGIS) or
endoscopy [19].
Although the NCSP for gastric cancer offers participants the
choice between UGIS and endoscopy screening, there is a lack of
agreement on which method is most effective for screening in the
general population. Thus, in the present study we estimated the
performance of UGIS and endoscopy screening in the average-risk
Korean population using the NCSP database. This study provides
detailed estimates of key performance measures of UGIS and
endoscopy screening: positivity rate, gastric cancer detection rate,
interval cancer rate (ICR), sensitivity, specificity, positive predic-
tive value (PPV), and stage distribution of screen-detected gastric
cancer by screening method.
Methods
Study population
The NCSP for gastric cancer invites Medical Aid recipients and
National Health Insurance (NHI) beneficiaries in the lower
income brackets and aged 40 years or older to participate in
gastric cancer screening. In 2002, NHI beneficiaries in the 20%
income bracket were eligible for the program. In 2003, the NCSP
expanded its target population to the 30% income bracket, and in
2005 the target population was further expanded to include NHI
beneficiaries in the lower 50% income bracket. The population for
the current study was restricted to individuals who participated in
the NCSP for gastric cancer between January 1, 2002 and
December 31, 2005. In total 2,318,558 participants underwent
gastric cancer screening at least once during this time period. We
excluded 54,804 participants (2.4%) due to missing screening
results, 3,440 (0.1%) due to missing information on screening
method, five because of incomplete identification numbers, and
9,917 (0.4%) due to a previous gastric cancer diagnosis according
to the Korean National Cancer Incidence Database (KNCIDB),
which contains 95% of newly diagnosed malignancies in Korea
[20]. The final study sample consisted of 2,250,392 participants
and 2,690,731 screening events.
The current study used the NCSP database, which includes
participants’ demographic characteristics and screening results,
and written informed consent given by participants for the
collection of their screening results and health data. We collected
these data regularly from the NHI Corporation. For this reason
obtaining informed consent for this specific study was waived due
to the large size of the NCSP database. This study was approved
by the institutional review board of the National Cancer Center,
Korea.
Gastric cancer screening and detection
Individuals invited to participate in the NCSP for gastric cancer
could choose to undergo either UGIS or endoscopy screening at a
clinic, or hospital designated as a gastric cancer screening unit by
the NHI Corporation. Results of both screening methods were
reported in seven categories (negative, peptic ulcer, benign tumor,
possible gastric cancer, early gastric cancer, advanced gastric
cancer, other). The results were defined as positive if the UGIS or
endoscopy result was coded as possible gastric cancer, early gastric
cancer, or advanced gastric cancer. Participants who had a
positive screening result on UGIS were contacted by telephone by
the medical staff of the gastric cancer screening unit, informed of
the positive result and offered a follow-up examination. Follow-up
examinations were performed within the framework of the NCSP.
However, the NCSP database does not include diagnostic test
results performed outside the program, as the NCSP database does
not capture tests paid for privately, or conducted as a medical care
service that is not part of screening.
Therefore, final gastric cancer diagnosis and tumor stage
information were ascertained through linkage with the KNCIDB
of the Korean Central Cancer Registry instead of using the NCSP
database. Gastric cancer diagnoses reported to the KNCIDB
through December 2006 were considered, to allow 12 months for
any diagnostic work-up to be completed and the results to be fully
reported. Tumor stages were recorded in the KNCIDB as
localized, regional, distant, or unknown neoplasms, in accordance
with the categories used in the Surveillance, Epidemiology, and
End Results (SEER) Cancer Statistics Review of the United States
National Cancer Institute [21].
Statistical analyses
We calculated performance measures for each screening
method. The positivity rate was calculated as the number of
positive results per 1,000 screening events. Gastric cancer
detection rate was calculated as the number of gastric cancer
cases detected per 1,000 screenings. Interval cancers were defined
as gastric cancer cases diagnosed outside the NCSP for gastric
cancer within 1 year of a negative screening result in the NCSP.
ICRs were calculated as the number of interval cancers per 1,000
screenings. Sensitivity was defined as the probability of a positive
screening result, given a finding of cancer within 1 year of
screening [true positive/(true positive+false negative)]. Specificity
was defined as the probability of a negative screening result, given
no finding of cancer within 1 year of screening [true negative/(true
negative+false positive)]. The PPV was estimated as the number of
screen-detected gastric cancer cases diagnosed per 100 positive
screenings. We further analyzed the distribution of tumor stages by
screening method and calculated the sensitivity of each screening
method to detect localized, and regional or distant gastric cancer.
All the performance measures were estimated by age group (40–
49, 50–64, $65 years), gender, and health insurance status.
Screening round was also considered in the calculations because
positivity rates and cancer detection rates vary based on whether
participants have previously undergone screening. The SAS
software package (ver. 9.1; SAS Institute Inc., Cary, NC, USA)
was used for all statistical calculations.
Performance of Gastric Cancer Screening in Korea
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Results
Study population characteristics
A total of 2,690,731 screening events for gastric cancer took
place between January 1, 2002 and December 31, 2005;
approximately, 66% were UGIS screenings and 34% were
endoscopy screenings. Endoscopy screening was chosen signifi-
cantly more often by younger men, and NHI beneficiaries
(p,0.001) (Table 1).
Performance of gastric cancer screening methods
Of the 1,765,909 UGIS and 924,822 endoscopy screening,
70,049 and 38,969, respectively, were positive (Table 2). The
positivity rate for endoscopy screening was statistically significantly
higher than that for UGIS screening, except among men aged 40–
49 and 50–59 years. The positivity rates of both UGIS and
endoscopy screening were higher in the first screening round than
in the subsequent round. Positivity rates also increased with
increasing age, and were higher in men than in women.
Among participants with positive UGIS and endoscopy
screening results, 1,196 and 2,415 gastric cancer cases were
detected, respectively. The gastric cancer detection rate of UGIS
screening was significantly lower (0.68 per 1,000 screenings) than
that of endoscopy screening (2.61 per 1,000 screenings) (Table 3).
However, the patterns between the two methods were similar; the
cancer detection rate was higher in the first screening round than
in the subsequent round, increased with age, and was higher in
men and Medical Aid recipients. With regard to interval cancer,
2,067 and 1,083 interval cancers occurred within 1 year of a
negative UGIS or endoscopy screening result, respectively
(Figure 1). The ICRs also increased with age and were higher in
men than in women. The ICR for UGIS screening (1.17/1,000
screenings) was not different from that of endoscopy screening
(1.17/1,000 screenings).
Sensitivity, specificity, and PPVs of gastric cancer
screening methods
The respective sensitivities of UGIS and endoscopy screening
were estimated at 36.7% and 69.0% (Table 4). The sensitivity of
endoscopy screening was statistically significantly higher than that
of UGIS. However, the specificity of UGIS and endoscopy
screening were not significantly different: 96.1% and 96.0%,
respectively. The sensitivity and specificity of UGIS and endos-
copy screening were not associated with screening round, gender,
age or health insurance type. The estimated PPV of UGIS
screening (1.7%) was statistically significantly lower than that of
endoscopy screening (6.2%). Overall, PPVs increased with age and
were higher in men than in women.
Distribution of tumor stages by screening method
Staging of screen-detected gastric cancer is shown in Table 5.
Localized cancer accounted for 32.4% and 45.7%, of gastric
cancer cases detected by UGIS and endoscopy screening,
respectively. To investigate which screening method was most
sensitive for the detection of early gastric cancer, we categorized
participants with gastric cancer into three groups according to
tumor stage (localized, regional or distant, and unknown) and
estimated corresponding sensitivities. The sensitivity of endoscopy
screening to detect localized gastric cancer was 65.7%, which was
statistically significantly higher than that of UGIS screening
(32.1%).
Discussion
This study reported population-based data from a large gastric
cancer screening program that allowed participants to choose
either UGIS or endoscopy as a screening method. In the present
study, only 34% of all gastric cancer screening was performed by
endoscopy, with younger men being more likely to choose this
method. However, the proportion of patients choosing endoscopy
screening increased annually during the study period, from 24.7%
in 2002 to 40.5% in 2005.
The positivity rate of endoscopy screening (42.1 per 1,000
screenings) was a little higher than that of UGIS screening (39.7
per 1,000 screenings). However, the gastric cancer detection rate
of endoscopy screening (2.61 per 1,000 screenings) was 3.9 times
higher than that of UGIS screening (0.68 per 1,000 screenings).
The higher gastric cancer detection rate of endoscopy screening
compared to UGIS screening was consistent across strata of
screening round, gender, and age. These results are consistent with
previous studies that compared the performance measures of
endoscopy and UGIS screening [16]. A study conducted in
Niigata, Japan, found that the gastric cancer detection rate of
endoscopy screening was between 2.7- and 4.6-fold higher than
that of UGIS or photofluorography screening [16,17]. In
agreement with previous reports, age and gender were associated
with the likelihood of cancer detection in our study.
For the present analysis, we used data collected as part of the
NCSP. Those who participated in the NCSP for gastric cancer
during the period under study selected the screening method
themselves, instead of being randomized. Therefore, differences in
gender, age, and type of health insurance distribution appeared
between those who underwent UGIS screening compared to
endoscopy screening. The percentage of males and NHI
beneficiaries was lower among those who underwent UGIS
Table 1. Characteristics of 2,250,392 participants who
underwent UGIS or endoscopy screening through the NCSP
for gastric cancer, 2002–2005.
UGISa Endoscopya Total
No. % No. % No. %
Total No. of screening 1,765,909 65.6 924,822 34.4 2,690,731 100.0
Screening year
2002 301,694 17.1 98,909 10.7 400,603 14.9
2003 396,713 22.5 172,760 18.7 569,473 21.2
2004 386,739 21.9 189,026 20.4 575,765 21.4
2005 680,764 38.6 464,127 50.2 1,144,891 42.5
Gender
Men 675,128 38.1 379,324 41.0 1,054,452 38.2
Women 1,090,782 61.7 545,498 59.0 1,636,280 61.8
Age (years)
40–49 503,454 28.5 341,348 36.9 844,802 31.4
50–59 522,239 29.6 3174049 34.3 839,643 31.2
60 and over 740,216 41.9 266,070 28.8 1,006,286 37.4
Health insurance type
Medical Aid recipients 302,804 17.2 48,815 5.3 351,619 13.1
NHI beneficiaries 1,463,106 82.8 876,007 94.7 2,339,113 86.9
UGIS, upper-gastrointestinal series; NCSP, National Cancer Screening Program;
NHI, national health insurance.
aAll differences between participants who underwent UGIS screening and those
who underwent endoscopy screening were statistically significant (p,0.001).
doi:10.1371/journal.pone.0050041.t001
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screening, but the percentage of participants aged 60 or over was
higher when compared with endoscopy screening. Since the
incidence of gastric cancer is higher in males, the elderly, and the
lower income group [22], the demographic differences between
those who underwent UGIS screening and endoscopy screening
may have been counterbalanced. Actually, the estimated age-
adjusted gastric cancer detection rate of endoscopy screening (2.69
per 1,000 screenings) was 3.5 times higher than that of UGIS
screening (0.76 per 1,000 screenings) (data not shown). The higher
gastric cancer detection rate of endoscopy screening may be partly
explained by the fact that endoscopy can identify a lesion involving
the mucosal surface of the stomach that conventional barium
examinations may miss [23].
In the present study, UGIS screening failed to detect 2,067 of
3,263 gastric cancer cases (63.6%), and endoscopy screening failed
to detect 1,083 of 3,498 cases (31.0%). These interval gastric
cancer cases may have occurred as a result of an undetected
abnormality at the time of screening (false-negative interval
cancers) or as a new event after a negative screening result (true
interval cancers) [24]. Unfortunately, this study could not
Table 2. Positivity rate for gastric cancer by screening method, NCSP for gastric cancer, 2002–2005.
UGIS Endoscopy
No. of screening
events
No. of positive
results
Positivity rate per
1,000 (95% CI)
No. of screening
events
No. of positive
results
Positivity rate per
1,000 (95% CI)
Total 1,765,909 70,049 39.7 (39.7–40.0) 924,822 38,969 42.1 (41.7–42.6)
Screening round
First round 1,484,579 60,403 40.7 (40.4–41.0) 765,813 32,589 42.6 (42.1–43.0)
Subsequent 281,330 9,646 34.3 (33.6–35.0) 159,009 6,380 40.1 (39.1–41.1)
Gender
Men 675,128 37,699 55.8 (55.3–56.4) 379,324 18,524 48.8 (48.1–49.5)
Women 1,090,781 32,350 29.7 (29.3–30.0) 545,498 20,445 37.5 (37.0–38.0)
Gender, age (years)
Men, 40–49 165,402 8,178 49.4 (48.4–50.5) 118,602 4,816 40.6 (39.5–41.8)
Men, 50–59 195,758 11,347 58.0 (56.9–59.0) 126,653 6,000 47.4 (46.2–48.6)
Men, 60+ 313,968 18,174 57.9 (57.0–58.7) 134,069 7,708 57.5 (56.1–58.8)
Women, 40–49 338,052 8,864 26.2 (25.7–26.8) 222,746 7,627 34.2 (33.5–35.0)
Women, 50–59 326,481 9,763 29.9 (29.3–30.5) 190,751 7,337 38.5 (37.6–39.3)
Women, 60+ 426,248 13,723 32.2 (31.7–32.7) 132,001 5,481 41.5 (40.4–42.6)
Health insurance type
Medical Aid recipients 302,803 10,334 34.1 (33.5–34.8) 48,815 2,076 42.5 (40.7–44.4)
NHI beneficiaries 1,463,106 59,715 40.8 (40.5–41.1) 876,007 36,893 42.1(41.7–42.5)
UGIS, upper-gastrointestinal series; CI, confidence interval; NHI, national health insurance.
doi:10.1371/journal.pone.0050041.t002
Figure 1. Diagram of gastric cancer screening in the NCSP.
doi:10.1371/journal.pone.0050041.g001
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distinguish false-negative from true interval cancers. However, as
the doubling time of gastric cancer is approximately 2–3 years
[25], most of the interval cancer cases in the present study were
considered false-negative cases, and false-negative interval cancers
were more likely to occur in participants who underwent UGIS
screening than endoscopy screening.
We calculated ICR as the number of gastric cancer cases
diagnosed within 1 year of a negative screening result per 1,000
screenings, and the ICR for UGIS screening was not different
from that of endoscopy screening. However, the NCSP recom-
mends biennial gastric cancer screening. Therefore we addition-
ally estimated the ICRs of UGIS and endoscopy screening during
the 2-year lapse between screening rounds. The ICRs for UGIS
and endoscopy screening increased slightly as the lapse length
increased; 1.89 (95% CI: 1.83–1.96) for UGIS screening, and 1.52
(95% CI: 1.44–1.60) for endoscopy screening (data not shown).
The ICR for UGIS during the 2-year lapse between screening
rounds was statistically significantly higher than that for endosco-
py.
PPV is one of the most important screening program
performance indicators, because high false-positive rates lead to
a large number of unnecessary investigations, with a negative
impact on cost-effectiveness. In the present study, the PPV of
endoscopy screening was 6.2%, which was approximately 3.4
times higher than that of UGIS screening (1.7%). Several studies
conducted in Japan have reported photofluorography PPVs
between 0.78 and 2.03% [13,26,27], which is slightly higher than
that of UGIS, but lower than that of endoscopy in this study.
Furthermore, the sensitivity of endoscopy screening (69.0%,
95% CI: 66.3–71.8) was higher than that of UGIS screening
(36.7%, 95% CI: 34.6–38.7) in the current study. However,
specificity was not statistically significantly different between the
Table 4. Sensitivity, specificity, and PPVs for detecting gastric cancer by screening method, NCSP for gastric cancer, 2002–2005.
UGIS Endoscopy
Sensitivity %
(95% CI)
Specificity %
(95% CI)
PPV %
(95% CI)
Sensitivity %
(95% CI)
Specificity %
(95% CI)
PPV %
(95% CI)
Total 36.7 (34.6–38.7) 96.1 (95.9–96.2) 1.7 (1.6–1.8) 69.0 (66.3–71.8) 96.0 (95.8–96.2) 6.2 (6.0–6.4)
Screening round
First 38.2 (35.9–40.5) 96.0 (95.8–96.2) 1.8 (1.7–1.9) 69.4 (66.4–72.4) 96.0 (95.8–96.2) 6.4 (6.1–6.6)
Subsequent 27.3 (22.6–32.0) 96.6 (96.3–97.0) 1.3 (1.1–1.6) 66.9 (59.8–74.0) 96.2 (95.7–96.7) 5.3 (4.8–5.9)
Gender
Men 37.7 (35.2–40.3) 94.5 (94.3–94.8) 2.2 (2.1–2.4) 68.4 (65.1–71.7) 95.5 (95.2–95.8) 9.0 (8.5–9.4)
Women 34.4 (30.9–38.0) 97.1 (96.9–97.3) 1.1 (1.0–1.3) 70.5 (65.5–75.5) 96.4 (96.1–96.6) 3.7 (3.4–4.0)
Gender, age (years)
Men, 40–49 36.6 (26.3–46.8) 95.1 (94.6–95.6) 0.6 (0.4–0.8) 71.7 (61.4–82.0) 96.1 (95.5–96.7) 3.8 (3.3–4.4)
Men, 50–59 37.3 (31.6–43.0) 94.4 (93.9–94.8) 1.4 (1.2–1.7) 67.4 (61.0–73.8) 95.6 (95.0–96.1) 7.2 (6.5–7.8)
Men, 60+ 37.9 (34.9–40.9) 94.4 (94.0–94.7) 3.4 (3.1–3.7) 68.3 (64.1–72.4) 95.0 (94.4–95.5) 13.6 (12.7–14.4)
Women, 40–49 33.1 (22.8–43.3) 97.4 (97.1–97.7) 1.1 (0.3–0.6) 73.1 (64.7–84.4) 96.6 (96.2–97.1) 2.1 (1.8–2.4)
Women, 40–59 28.4 (21.1–35.7) 97.0 (96.7–97.4) 0.6 (0.4–0.7) 70.7 (61.4–79.9) 96.3 (95.8–96.7) 3.1 (2.7–3.5)
Women, 60+ 36.3 (32.0–40.7) 96.8 (96.5–97.1) 2.0 (1.7–2.2) 69.3 (62.3–76.4) 96.1 (95.6–96.6) 6.8 (6.1–7.5)
Health insurance type
Medical Aid recipients 38.5 (33.7–43.3) 96.7 (96.3–97.0) 2.4 (2.1–2.7) 68.0 (57.2–78.8) 96.0 (95.2–96.9) 7.4 (6.2–8.5)
NHI beneficiaries 36.2 (33.9–38.5) 96.0 (95.8–96.1) 1.6 (1.5–1.7) 69.1 (66.3–72.0) 96.0 (95.8–96.2) 6.1 (5.9–6.4)
PPV, positive predictive value; UGIS, upper-gastrointestinal series; CI, confidence interval; NHI, national health insurance.
doi:10.1371/journal.pone.0050041.t004
Table 5. Sensitivity of difference screening methods to detect gastric cancer by stage, NCSP for gastric cancer, 2002–2005.
UGIS Endoscopy
Screen-detected gastric
cancer No. (%)
Sensitivity %
(95% CI)
Screen-detected gastric
cancer No. (%)
Sensitivity %
(95% CI)
Stagea
Localized 388 (32.4) 32.1 (28.9–35.3) 1103 (45.7) 65.7 (61.8–69.5)
Regional or distant 381 (31.9) 37.8 (34.0–41.6) 543 (22.5) 73.6 (67.4–79.8)
Unknown 427 (35.7) 40.7 (36.9–44.6) 769 (31.8) 71.2 (66.2–76.2)
UGIS, upper-gastrointestinal series; CI, confidence interval.
aThe following stage definitions were applied (adapted from the SEER Cancer Statistics Review); localized, a neoplasm confined entirely to the stomach without serosal
involvement; regional, a neoplasm that extends beyond the limits of the stomach and invades the surrounding tissue; distant, a neoplasm that spreads to parts of the
body remote from the primary tumor; unknown, a neoplasm with insufficient or unavailable information to assign a stage.
doi:10.1371/journal.pone.0050041.t005
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two screening methods. Previous studies have found that the
sensitivity of photofluorography screening ranged from 56.8% to
88.5% [13,27,28,29], whereas that of endoscopy screening
fluctuated between 77.8% and 84.0% [30,31]. Our sensitivity
results were lower than those reported by others for both UGIS
and endoscopy screening. However, it is difficult to directly
compare the results of different studies due to differences in the
target populations and in the gastric cancer screening programs
themselves.
To compare the performance of UGI and endoscopy for
detection of gastric cancer in population-based screening, we
calculated the area under curve (AUC) using the summary receiver
operating characteristic (SROC) curve. SROC curves were
constructed using an estimated 1-specificity and sensitivity. We
calculated AUC according to the Moses method, by extrapolating
curves to the corners of SROC [32]. There is no absolute AUC
threshold that defines a ‘‘good’’ test. However, an AUC of 1.0
defines a ‘‘perfect’’ test, and an AUC of 0.5 defines a ‘‘useless’’ test
[33]. The AUCs of UGI and endoscopy were 0.6197 (95% CI:
0.4429–0.7965), and 0.9413 (95% CI: 0.9344–0.9482), respective-
ly, and the AUC of endoscopy was statistically significantly higher
than that of UGIS (p,0.001).
Tumor stage is an important prognostic factor following a
diagnosis of gastric cancer. There is only very limited evidence to
support the superiority of endoscopy screening over radiology
screening methods for the detection of early gastric cancer. In this
study, 45.7% of gastric cancer cases detected by endoscopy
screening were localized, whereas the figure for UGIS screening
was 32.4%. Furthermore, our data showed that endoscopy
screening was statistically significantly more sensitive than UGIS
screening to detect localized gastric cancer: 65.7% and 32.1%,
respectively. Previous studies have reported that endoscopy
screening was suitable for diagnosis of a lesion involving the
mucosal surface of the stomach [23]. Nishizawa et al [34] stated
that endoscopy was more effective than a barium meal study for
the detection of early gastric cancer. Kubota et al [35] also found
that endoscopy screening allowed for the detection of smaller
gastric tumors than did radiography screening.
The present study has some limitations. First, we could not
distinguish between symptomatic and asymptomatic participants.
Those with symptoms would be more likely to have abnormal
results and a diagnostic follow-up versus asymptomatic partici-
pants. Furthermore, there were substantial differences in the
characteristics of participants who underwent UGIS screening and
those who underwent endoscopy screening. These differences
might have affected the positivity rate, gastric cancer detection
rate, ICR and PPV, because these indicators depend on the
prevalence of a given disease in the population. However,
sensitivity and specificity, which were the key estimates of this
study, are prevalence-independent test characteristics, as their
values are intrinsic to the test and do not depend on the prevalence
of a given disease in the population of interest. Therefore, the
differences in characteristics between those who underwent UGIS
screening and those who underwent endoscopy screening had a
relatively small effect on sensitivity and specificity. Nevertheless, to
minimize the confounding effect of non-randomization, all the
performance measures were estimated by age group, gender, and
health insurance type in the current study. We used health
insurance type (Medical Aid vs. NHI) as a proxy for socioeconomic
status. These indicators have been regarded as a highly reliable
proxy for income. However, as we could not consider a
participant’s educational level or occupation as a proxy for
socioeconomic status, it is possible that the socioeconomic status of
participants was not fully reflected. Further, we couldn’t consider
histopathological features of the tumor such as histological
differentiation, Lauren classification, and tumor location that
might that might influence gastric cancer detection rate of UGIS
and endoscopy screening. Second, although the NCSP is a
population-based screening program, our study results may not be
generalizable due to a low participation rate. Overall, approxi-
mately 13.4% of invited individuals were screened, and self-
selection of participants cannot be excluded. However, it is not
likely that these factors alone can explain the magnitude of the
observed effect, and the overall detection rates reported in this
study were comparable to those of other studies. Third, data
available in the NCSP database does not include referral
information or diagnostic test results conducted outside of the
organized screening program (i.e. outpatient clinics, or private
screening centers). Therefore, it was possibile that people who
didn’t attend follow-up within the NCSP were lost. To minimize
loss to follow-up, we used the KNCIDB instead of the NCSP
database to ascertain diagnosis of gastric cancer. The percentage
of subjects in the KNCIDB that had to be identified by death
certificate notification for 2003–200 was 4.7% for men and 4.3%
for women, which shows the completeness of the KNCIDB [20],
and suggests that it might be possible to disregard any bias due to
loss to follow-up.
Overall, the better performance of endoscopy compared with
UGIS screening supports the hypothesis that endoscopy screening
may have a larger impact on gastric cancer mortality [16,35,36].
However, data on the impact of endoscopy screening programs on
gastric cancer mortality are limited [35,37,38,39]. Thus, further
study is needed to determine whether endoscopy screening is more
effective than radiography screening in reducing mortality.
Although the data presented here are preliminary, our interme-
diate outcomes indicate that, in Korea, the introduction of
endoscopy screening for gastric cancer in the average-risk
population appears to perform better than UGIS screening.
Further evaluation of the impact of these screening methods
should take into account both cost and any associated reduction in
gastric cancer mortality.
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